Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1480 · 1 trial · 3 indications
Single dose AUC0-12 (ug\*h/L)
Single dose AUC0-24 (ug\*h/L)
Single dose AUC(0 to infinity) (ug\*h/L)
Multiple dose Cmax,ss (ug/L)
Multiple dose Cmin,ss (ug/L)
Single dose Cmax (ug/L)
Single dose Vz/F (L)
Single dose CL/F (L/h)
Multiple dose CLss/F (L/h)
Single dose Tmax (h)
Multiple dose Tmax,ss (h)
PSTAT3 inhinition
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1480 |
| Name | Type | Description |
|---|---|---|
| AZD1480 | DRUG | Oral capsule 2.5 mg, 10 mg and 40 mg |
Inclusion Criteria: * Patients with myelofibrosis requiring therapy * Evidence of post-menopausal status or sterile * ECOG Performance Status \</=2 Exclusion Criteria: * Prior therapy with any JAK2 medications * Significant lung disorder or lung disease * Previous radiation therapy to chest wall ...
AZD1480 is an investigational small molecule being studied for the treatment of Primary Myelofibrosis (PMF), as well as Post-Polycythaemia Vera and Essential Thrombocythaemia Myelofibrosis. It is being developed by AstraZeneca PLC (AZN) and is currently in Phase 1 clinical development.
AZD1480 is a small molecule being studied for its potential to treat myeloproliferative diseases, including Primary Myelofibrosis. Its specific molecular target has not been disclosed, and its mechanism of action is not fully characterized in available clinical data.
AZD1480 is being developed by AstraZeneca PLC, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for the treatment of Primary Myelofibrosis and related myeloproliferative conditions.
AZD1480 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and potential efficacy in patients with Primary Myelofibrosis and other myeloproliferative diseases.
AZD1480 has been studied in one completed Phase 1 clinical trial with the identifier NCT00910728. This trial, titled "Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases," enrolled 65 participants and was conducted in the United States and France.
AZD1480 is a distinct investigational compound developed by AstraZeneca. No alternative names have been reported for this drug in the available clinical trial information, and it is not known to be identical to any other marketed or investigational medication.